Skip to content
Bored Studies
RecruitingPhase 1

A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity

Eli Lilly and Company · NCT07803744

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–70 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1
Target enrollment
18
US sites recruiting
1
Study start
September 11, 2026
Record last updated
September 23, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The main purpose of this study is to learn more how tirzepatide affects stomach emptying in participants with Type 1 Diabetes Mellitus (T1DM) and overweight or obesity.

Participation in this study will last about 8 weeks, including screening and follow-up.

Being studied: Tirzepatide; Acetaminophen; Placebo

Conditions: Diabetes Mellitus, Type 1; Overweight; Obesity

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Have a diagnosis of type 1 diabetes mellitus (T1DM) and have been treated with insulin for at least 1 year prior to screening
  • Have a body mass index (BMI) greater than or equal to 25.0 kilograms per square meter (kg/m2) at screening
  • Are of stable weight, that is a self-reported change of 5 kg or less, for at least 90 days prior to screening

Exclusion Criteria

  • Participants who have a known clinically significant gastric emptying abnormality
  • Have undergone weight loss surgery such as gastric bypass (bariatric) surgery or restrictive bariatric surgery
  • Have known allergies or intolerance to acetaminophen, tirzepatide, or glucagon-like peptide-1 (GLP-1) receptor agonists

Recruiting US locations

  • Clinical Pharmacology of Miami

    Miami, FL 33172

    Site contact: 305-817-2900

Study contacts (from the official record)

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
  • Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
All weight loss studies in Florida →
A Study of Tirzepatide (LY3298176) in Participants With Type 1… (NCT07803744) | Bored Studies